BRISTOL MYERS SQUIBB ACQUIRES CAMBRIDGE ANTIBODY TECHNOLOGY

Highlights

• Along with the initial payment, the US pharma company will also pay for maintenance, the achievement of development milestones and eventual royalty payments on all antibodies derived from the platform

• This IONTAS’ technology helps bring down the risk of antibodies failing at the time of expensive manufacturing stages

• The company is excited to have Bristol Myers Squibb, one of ....